Fulcrum Therapeutics (FULC) Research & Development (2018 - 2026)
Fulcrum Therapeutics (FULC) posted quarterly Research & Development of $12.4 million for Q2 2026, down 4.18% year-over-year from $13.0 million in Q2 2025, and down 11.64% quarter-over-quarter from $14.1 million in Q1 2026.
Fulcrum Therapeutics (FULC) Research & Development (2018 - 2026) Analysis & Trends
Fulcrum Therapeutics (FULC) has reported Research & Development for 9 consecutive years, with $12.4 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Research & Development fell 4.18% year-over-year to $12.4 million; the TTM figure through Jun 2026 stood at $56.2 million (up 6.63% YoY), while the FY2025 annual figure was $56.1 million, down 11.49% from the prior year.
- Research & Development retreated to $12.4 million in Q2 2026 per FULC's latest filing, from $14.1 million in the prior quarter.
- Across five years, Research & Development topped out at $25.0 million in Q2 2022 and bottomed at $11.7 million in Q4 2024.
- Historically, Research & Development has averaged $16.4 million across 5 years, with a median of $16.1 million in 2023.
- Annual changes were most pronounced in 2022 — Research & Development soared 43.97% — and 2024, when it plunged 38.35%.
- Fulcrum Therapeutics' Research & Development stood at $18.6 million in 2022, then increased by 2.33% to $19.0 million in 2023, then slumped by 38.35% to $11.7 million in 2024, then surged by 31.61% to $15.4 million in 2025, then dropped by 19.28% to $12.4 million in 2026.
- Business Quant data shows FULC's Research & Development at $12.4 million in Q2 2026, $14.1 million in Q1 2026, and $15.4 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | Fulcrum Therapeutics | 285.31 Mn | 285.31 Mn | - | 12.44 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 12.44 Mn |
| Mar 31, 2026 | 14.08 Mn |
| Dec 31, 2025 | 15.42 Mn |
| Sep 30, 2025 | 14.30 Mn |
| Jun 30, 2025 | 12.99 Mn |
| Mar 31, 2025 | 13.40 Mn |
| Dec 31, 2024 | 11.71 Mn |
| Sep 30, 2024 | 14.64 Mn |
| Jun 30, 2024 | 17.26 Mn |
| Mar 31, 2024 | 19.77 Mn |
| Dec 31, 2023 | 19.00 Mn |
| Sep 30, 2023 | 18.24 Mn |
| Jun 30, 2023 | 17.85 Mn |
| Mar 31, 2023 | 16.72 Mn |
| Dec 31, 2022 | 18.57 Mn |
| Sep 30, 2022 | 15.37 Mn |
| Jun 30, 2022 | 25.02 Mn |
| Mar 31, 2022 | 17.83 Mn |
| Dec 31, 2021 | 18.91 Mn |
| Sep 30, 2021 | 17.08 Mn |